Bayer's ErSO therapy for metastatic breast cancer has not yet entered clinical trials
- Last Update: 2021-12-31
- Source: Internet
- Author: User
Previously, it was reported that ErSO, a small molecule drug from Bayer, has a 95% to 100% success rate for the treatment of cancer cells in animals
This therapy ErSO is a new drug developed by researchers at the University of Illinois in the United States.
In September 2020, Bayer signed an agreement to purchase the development license for the drug for US$370 million and cooperated with Arizona-based Systems Oncology to develop the drug
However, according to the latest reports, since the partnership between the two companies is no longer effective, the two companies' cooperation project on the tumor therapy has also reached a deadlock
Metastatic estrogen receptor-positive breast cancer is the most common type of breast cancer, and there is currently no cure.
ErSO Activism manager Danny Goss expressed his disappointment.
At the same time, Professor Shapiro and his team said they will continue to study ErSO therapy
- The Market Supervision Office of Longmen Town, Lintao County, Gansu Province, carried out a special inspection of food safety before the "Double Festival"
- Longmen Town, Lintao County, Gansu Province, launched a large-scale investigation and major renovation of the starch processing industry
- Top 10 global CRO companies in 2021
- Can cancer patients eat chicken essence
- Is yogurt alkaline or acidic?
- The difference between PU and NC wood paint Seven differences to look at carefully
- Benxi biological hepatitis B and AIDS test box have been registered. Two products can be put into production this month
- The Market Supervision Office of Longmen Town, Lintao County, Gansu Province, launches a special inspection of school food safety in the fall of 2021
- What is Weilin
- What is cereal alcohol? Is it dangerous to use it for food and wine?
Moreover, if you find any instances of plagiarism from the page, please send email to firstname.lastname@example.org with relevant evidence.